EGFR and breast carcinoma: Data from earlier clinical studies of BL‐B01D1 were presented in 2023 at the American Society of Clinical Oncology, European Society for Medical Oncology (ESMO) and the San Antonio Breast Cancer Symposium; these data demonstrated impressive antitumor activity in patients with EGFR‐TKI resistance, with an ORR of 63.2%.345